EPOCH: Phase III Trial Comparing Transarterial Radioembolization With Yttrium-90 + Second-line CT vs CT Only in Patients With Unresectable Colorectal Liver Metastases

September 16-21, 2021; Virtual
In patients with colorectal cancer and unresectable liver metastases, the addition of transarterial radioembolization with yttrium-90 to second-line chemotherapy demonstrated significant improvements in PFS and hepatic PFS with a higher rate of grade ≥3 toxicity.
Format: Microsoft PowerPoint (.ppt)
File Size: 317 KB
Released: October 1, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Exelixis, Inc.
Ipsen Biopharmaceuticals, Inc.

Related Content

Phase II trial evaluating pemigatinib for previously treated mCRC with FGF/FGFR alterations, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

MOUNTAINEER concordance analysis between breast and gastric algorithms for HER2 testing in mCRC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

SUNLIGHT trial of the addition of bevacizumab to third-line TAS-102 in refractory mCRC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

In slides from Clinical Care Options (CCO), experts provide perspectives on updates in biomarker testing and targeted therapy across GI cancers

John L. Marshall, MD
Program Director
Christopher H. Lieu, MD Manish A. Shah, MD
Released: January 19, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings